Bevacizumab: improved survival at what cost?
Kolesar
Jill M
JM
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D000068258:Bevacizumab; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013534:Survival; D014481:United States; D014486:United States Food and Drug Administration
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab